Quick answer
What is Afamelanotide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Afamelanotide is a peptide, grouped on this site under Melanocortin receptor peptides, and the 12 research records kept here are 1 from a trial in people and 11 that do not state what kind of study it is.
The literature search returned 105 records. This site keeps 12 of them, which is 11 per cent of what came back.
What it is
This site puts it in the Melanocortin receptor peptides group.
An alpha-melanocyte-stimulating hormone analogue acting at melanocortin receptors, with the retrieved clinical literature concentrated on pigmentary endpoints.[1, 2]
Taken from the pigmentary indications stated in the cited 2015 New England Journal of Medicine and 2013 JAMA Dermatology titles, together with the class definition.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 1 interventional human trial record among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 93 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med (2015). pmid:26132941
- The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol (2013). pmid:23407924